| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
\(H_1\) receptor (IC50 = 44 nM, 95% CI 26-68)
\(\alpha_1\) receptor (IC50 = 8 nM, 95% CI 6-10) \(M_1\) receptor (IC50 = 46 ± 12 nM) \(M_2\) receptor (IC50 = 7300 ± 2900 nM) 5-HT₁A receptor (40% inhibition at 1 μM) \(D_2\) receptor (41% inhibition at 1 μM) [1] |
|---|---|
| ln Vitro |
At a dosage of 100 nM, Wy 49051 exhibits a 92% reduction of histamine-induced ileal contraction in guinea pigs, demonstrating its strong inhibitory activity on H1. The most potent substance was Wy 49051, which had a potency 700 times more than astemizole and 470 times greater than chlorpheniramine. With an IC50 of 8 nM, Wy 49051 likewise exhibits significant affinity for α1 receptors[1].
At a concentration of \(1 × 10^{-7}\) M, WY-49051 competitively antagonized the histamine-induced contractile response of the isolated guinea pig ileum with 92% inhibition, showing a \(pA_2\) value of 11, confirming it as a competitive \(H_1\)-antagonist [1] It is more potent than reference antihistamines: 700 times more potent than astemizole, 470 times more potent than chlorpheniramine, 840 times more potent than compound 17, and more potent than ebastine (\(pA_2=7.4\)) and terfenadine (\(pA_2=7.5\)) [1] It exhibits potent affinity for \(H_1\)-receptors and weak affinity for dopamine and 5-HT₁A receptors [1] Despite high affinity for the \(\alpha_1\) receptor, it does not induce adverse cardiovascular effects in spontaneously hypertensive rats (SHR) at doses exceeding its \(H_1\)-antagonist effective dose [1] |
| ln Vivo |
In guinea pigs, Wy 49051 exhibited strong antihistamine-induced fatal action, with an ED50 of 1.91 mg/kg orally, 0.70 mg/kg intraperitoneally, and 0.01 mg/kg intravenously administered. Additionally, the 24-hour duration of action is advantageous because oral efficacy does not decline for up to 18 hours following therapy [1].
In the guinea pig histamine-induced lethality test, WY-49051 shows dose-dependent protective effects: ED50 = 1.91 mg/kg (95% CI 1.20-3.02) via oral (PO) administration, 0.70 mg/kg (95% CI 0.22-2.23) via intraperitoneal (ip) administration, and 0.01 mg/kg (95% CI 0.00-0.10) via intravenous (iv) administration at 1 hour post-treatment [1] Oral efficacy remains unchanged for up to 18 hours post-administration, demonstrating a long duration of action [1] In the guinea pig histamine-induced skin wheal formation test, it antagonizes cutaneous vascular permeability: ED50 = 0.42 mg/kg (no CI) at 2 hours and 1.14 mg/kg (95% CI 1.02-1.40) at 18 hours post oral administration, with potency comparable to chlorpheniramine [1] Onset of action is faster than astemizole and terfenadine but slower than ebastine; duration of action exceeds 18 hours; efficacy is comparable to 17, astemizole, and ebastine at 8 hours, slightly more efficacious than 17 and ebastine (but less than astemizole) at 18 hours [1] |
| Enzyme Assay |
In vitro neuroreceptor binding assays: Measure the ability of WY-49051 to displace radioligands from various receptors (H₁, \(\alpha_1\), \(M_1\), \(M_2\), 5-HT₁A, \(D_2\)); experiments are repeated 3-4 times, with IC50 values calculated (95% CI for single determinations or ±SEM for multiple determinations); for receptors without full inhibition curves, percentage inhibition at 1 μM is recorded [1]
Guinea pig ileum histamine-induced contraction assay: Use a modified method of Van Neuten and Janssen; treat isolated guinea pig ileum with histamine, observe the inhibitory effect of WY-49051 on contractile responses, calculate inhibition rate at \(1 × 10^{-7}\) M, and determine \(pA_2\) value to assess antagonism type and potency [1] |
| Animal Protocol |
Histamine-induced lethality test in guinea pigs: Administer WY-49051 and reference antihistamines at 1 mg/kg PO, challenge with histamine (1.25 mg/kg iv) at different time intervals to evaluate duration of action; for ED50 determination, administer WY-49051 via PO/ip/iv routes, challenge with histamine at 1 hour post-administration, and record protective effects [1]
Histamine-induced skin wheal formation test in guinea pigs: Orally administer WY-49051, challenge with histamine at 2 hours and 18 hours post-administration, measure wheal formation, and calculate ED50 values [1] Spontaneous motor activity test in rats: Treat male rats with vehicle (0.25% Tween 80) or WY-49051 via ip at various doses; after 15-minute acclimation in a motor activity chamber, assess rearing activity for 15-minute intervals over 1 hour to detect sedative effects [1] Rotorod test in rats: Administer WY-49051 at 20 mg/kg ip, observe for sedative/ataxic effects [1] Adverse cardiovascular effect test in SHR: Administer WY-49051 at doses higher than its \(H_1\)-antagonist effective dose, monitor cardiovascular parameters to evaluate potential adverse effects [1] |
| ADME/Pharmacokinetics |
Octyl alcohol-water partition coefficient (log P) = 1.77, its lipophilicity is significantly lower than that of terfenadine (log P = 2.35) and ebastine (log P = 2.74) [1]
It is effective orally; unlike ebastine, its (H_1) receptor antagonistic activity does not depend on the production of active metabolites, and it still has strong activity after intravenous administration [1] It has a long duration of action, and the oral efficacy can last up to 18 hours after treatment [1] |
| Toxicity/Toxicokinetics |
In activity restriction tests, WY-49051 did not induce significant sedation (unlike terfenadine, which induces sedation at intraperitoneal injection of 1–10 mg/kg)[1]
In rotarod tests, no sedation/ataxia was observed at intraperitoneal injection of 20 mg/kg[1] In SHR, no adverse cardiovascular reactions were observed at doses exceeding the effective dose of its (H_1) receptor antagonist[1] |
| References | |
| Additional Infomation |
WY-49051 (compound 24) is a novel xanthine-substituted piperidine derivative synthesized by replacing the polycyclic imide group of compound 8 with a xanthine group, thereby eliminating undesirable anti-dopaminergic activity while retaining potent (H1) receptor antagonist properties [1]. It is a potent oral (H1) receptor antagonist with good central nervous system properties and is available for licensing worldwide [1]. Further central nervous system testing and extensive receptor screening are needed to elucidate its potential central nervous system effects and (α1) receptor-related activities [1].
|
| Molecular Formula |
C28H33N5O3
|
|---|---|
| Molecular Weight |
487.593326330185
|
| Exact Mass |
487.258
|
| CAS # |
113418-56-7
|
| PubChem CID |
6918138
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.5
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
36
|
| Complexity |
728
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(C1C=CC=CC=1)C1C=CC=CC=1)C1CCN(CCCN2C=NC3=C2C(N(C)C(N3C)=O)=O)CC1
|
| InChi Key |
YNDYDETWRDHMLW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C28H33N5O3/c1-30-26-24(27(34)31(2)28(30)35)33(20-29-26)17-9-16-32-18-14-23(15-19-32)36-25(21-10-5-3-6-11-21)22-12-7-4-8-13-22/h3-8,10-13,20,23,25H,9,14-19H2,1-2H3
|
| Chemical Name |
7-[3-(4-benzhydryloxypiperidin-1-yl)propyl]-1,3-dimethylpurine-2,6-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0509 mL | 10.2545 mL | 20.5090 mL | |
| 5 mM | 0.4102 mL | 2.0509 mL | 4.1018 mL | |
| 10 mM | 0.2051 mL | 1.0255 mL | 2.0509 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
